Literature DB >> 14969654

Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials.

Alain J Nordmann1, Peter Hengstler, Thomas Harr, James Young, Heiner C Bucher.   

Abstract

PURPOSE: To examine whether primary stenting as compared with primary balloon angioplasty reduces clinical outcomes in patients with myocardial infarction.
METHODS: Major medical databases from 1979 to March 2002 were searched for randomized controlled trials that compared primary stenting with balloon angioplasty in patients with myocardial infarction. Two independent reviewers selected and extracted data from identified trials. The outcomes were mortality at 30 days, 6 months, and 12 months; recurrent events; and bleeding.
RESULTS: Nine trials with a total of 4433 patients fulfilled the inclusion criteria. The odds ratios for mortality after stenting as compared with balloon angioplasty were 1.17 (95% confidence interval [CI]: 0.78 to 1.74) at 30 days, 1.07 (95% CI: 0.76 to 1.52) at 6 months, and 1.09 (95% CI: 0.80 to 1.50) at 12 months (P for heterogeneity >0.1 for each comparison). The odds ratios for reinfarction after stenting as compared with balloon angioplasty were 0.52 (95% CI: 0.31 to 0.87) at 30 days, 0.67 (95% CI: 0.45 to 1.00) at 6 months, and 0.67 (95% CI: 0.45 to 0.99) at 12 months; for target vessel revascularization, they were 0.46 (95% CI: 0.34 to 0.61) at 30 days, 0.42 (95% CI: 0.35 to 0.51) at 6 months, and 0.48 (95% CI: 0.39 to 0.59) at 12 months (P for heterogeneity >0.1 for all estimates with the exception of reinfarction at 12 months where P=0.08). The odds ratio for postinterventional bleeding complications after stenting as compared with balloon angioplasty was 1.34 (95% CI: 0.95 to 1.88; P for heterogeneity >0.1).
CONCLUSION: Compared with balloon angioplasty, primary stenting is not associated with lower mortality, but is associated with a lower risk of reinfarction and target vessel revascularization.

Entities:  

Mesh:

Year:  2004        PMID: 14969654     DOI: 10.1016/j.amjmed.2003.08.035

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

1.  Double jeopardy in acute ST-segment elevation myocardial infarction.

Authors:  Rajiv Ananthakrishna; Li-Jun Wang; Liang Ping Zhao; Huay Cheem Tan
Journal:  Singapore Med J       Date:  2017-04       Impact factor: 1.858

Review 2.  Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in India.

Authors:  Santanu Guha; Rishi Sethi; Saumitra Ray; Vinay K Bahl; S Shanmugasundaram; Prafula Kerkar; Sivasubramanian Ramakrishnan; Rakesh Yadav; Gaurav Chaudhary; Aditya Kapoor; Ajay Mahajan; Ajay Kumar Sinha; Ajit Mullasari; Akshyaya Pradhan; Amal Kumar Banerjee; B P Singh; J Balachander; Brian Pinto; C N Manjunath; Chandrashekhar Makhale; Debabrata Roy; Dhiman Kahali; Geevar Zachariah; G S Wander; H C Kalita; H K Chopra; A Jabir; JagMohan Tharakan; Justin Paul; K Venogopal; K B Baksi; Kajal Ganguly; Kewal C Goswami; M Somasundaram; M K Chhetri; M S Hiremath; M S Ravi; Mrinal Kanti Das; N N Khanna; P B Jayagopal; P K Asokan; P K Deb; P P Mohanan; Praveen Chandra; Col R Girish; O Rabindra Nath; Rakesh Gupta; C Raghu; Sameer Dani; Sandeep Bansal; Sanjay Tyagi; Satyanarayan Routray; Satyendra Tewari; Sarat Chandra; Shishu Shankar Mishra; Sibananda Datta; S S Chaterjee; Soumitra Kumar; Soura Mookerjee; Suma M Victor; Sundeep Mishra; Thomas Alexander; Umesh Chandra Samal; Vijay Trehan
Journal:  Indian Heart J       Date:  2017-03-23

3.  Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection.

Authors:  Vikas Singh; Mauricio G Cohen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-05

Review 4.  Current Indications for Stenting: Symptoms or Survival CME.

Authors:  Suzanne V Arnold
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jan-Mar

5.  BOLD cardiac MRI for differentiating reversible and irreversible myocardial damage in ST segment elevation myocardial infarction.

Authors:  Bing-Hua Chen; Ruo-Yang Shi; Dong-Aolei An; Rui Wu; Chong-Wen Wu; Jiani Hu; Amanda Manly; Hisham Kaddurah; Jie He; Jun Pu; Jian-Rong Xu; Lian-Ming Wu
Journal:  Eur Radiol       Date:  2018-07-09       Impact factor: 5.315

6.  Drug-eluting stents versus bare metal stents in ST elevation myocardial infarction at a follow-up of three years or longer: A meta-analysis of randomized trials.

Authors:  Ankur Sethi; Amol Bahekar; Rohit Bhuriya; Anurag Bajaj; Daniela Kovacs; Aziz Ahmed; Sandeep Khosla
Journal:  Exp Clin Cardiol       Date:  2012

7.  Cardiac MRI of myocardial salvage at the peri-infarct border zones after primary coronary intervention.

Authors:  Declan P O'Regan; Rizwan Ahmed; Clare Neuwirth; Yvonne Tan; Giuliana Durighel; Joseph V Hajnal; Imad Nadra; Simon J Corbett; Stuart A Cook
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-08       Impact factor: 4.733

Review 8.  A quantitative estimate of bare-metal stenting compared with balloon angioplasty in patients with acute myocardial infarction: angiographic measures in relation to clinical outcome.

Authors:  Tone Svilaas; Iwan C C van der Horst; Felix Zijlstra
Journal:  Heart       Date:  2007-07       Impact factor: 5.994

9.  Clinical Outcomes of Acute Myocardial Infarction Patients With a History of Malignant Tumor.

Authors:  Masashi Nozaka; Hiroaki Yokoyama; Kazutaka Kitayama; Daiki Nagawa; Misato Hamadate; Naotake Miura; Yosuke Kawamura; Masamichi Nakata; Fumie Nishizaki; Kenji Hanada; Takashi Yokota; Masahiro Yamada; Hirofumi Tomita
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

10.  Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.

Authors:  Jens Wiebe; Helge Möllmann; Astrid Most; Oliver Dörr; Kay Weipert; Johannes Rixe; Christoph Liebetrau; Albrecht Elsässer; Stephan Achenbach; Christian Hamm; Holger Nef
Journal:  Clin Res Cardiol       Date:  2013-10-18       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.